The first ever Informex Biotech Breakfast was held on Tuesday, 27 January and featured four presentations on trends, opportunities and strategies for companies looking to build outsourcing relationships with the biopharmaceutical industry. A key theme running across the presentations was the position of contract manufacturing organizations (CMOs) as an integral part of a biotech sector that is maturing and becoming increasingly focused on cost efficiencies.
For Eric Langer, President of BioPlan Associates, the near-term future of the biopharmaceutical contract manufacturing market holds promise despite the economic climate. "We've all seen the reports that say that 30% of the biopharma industry has only 6 months of cash, that IPOs are down 97% and that venture financing is down 30%," said Langer. "Beneath the surface, a close look at what is actually happening in the market reveals significant opportunities for growth in equipment, raw materials and services," Langer's Sixth Annual Report & Survey on Biopharmaceutical Manufacturing, to be published shortly, set the growth in total sales in these categories at 13.3% in 2008.
Selected opportunities also were revealed in a presentation by Bill Downey of High Tech Business Decisions on supply trends, strategies
Copyright©2009 PR Newswire.
All rights reserved